Clarivate™

Sample content

Type 2 Diabetes

Disease Landscape & Forecast

Published: December 2024

About Disease Landscape & Forecast

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

What are the sizes of the diagnosed, drug-treatable, and/or drug-treated populations?

What is the current treatment landscape?

What products are in development, and what is their launch potential and future positioning?

What is the market outlook of sales and patient share for the next 10 years?

What are the drivers and constraints of market growth, and what events will most impact the market's trajectory?

What unmet needs and opportunities exist?

Clarivate™

Methodology and scope

Market forecast

- **Forecast:** Annualized drug-level sales and patient share of key type 2 diabetes therapies from 2023-2033, segmented by brands/generics.

- **Epidemiology:** Total, diagnosed, and drug-treated prevalent cases of type 2 diabetes by country.

- **Market segmentations:** Type 2 diabetes patients who are 20 years or older.

- **Additional content:** Downloadable Excel files containing detailed forecast assumptions and visual outputs.

Primary market research

- Interviews with 17 thought-leading diabetologists and endocrinologists across the G7.

- Data and insights leveraged from physician surveys conducted by Clarivate in type 2 diabetes to model current and future market dynamics.

Geography

United States   EU5   Japan

Key therapies covered

Phase 3	• Retatrutide (Eli Lilly) • Orforglipron (Eli Lilly) • IcoSema (Novo Nordisk)
Marketed	• Tirzepatide (Mounjaro) • SC semaglutide (Ozempic) • Empagliflozin (Jardiance)

Clarivate™

Report table of contents

1. **Executive Summary**
2. **Key Updates**
3. **Market Forecast**
   - Key takeaways
   - Market drivers and constraints
   - Drug class-specific trends
4. **Disease Context**
5. **Epidemiology**
   - Key takeaways
   - Total prevalent cases of type 2 diabetes
   - Diagnosed and drug-treated populations

6. **Current Treatment**
   - Key takeaways
   - Treatment for type 2 diabetes
   - Key current therapies
7. **Emerging Therapies**
   - Key takeaways
   - Key emerging therapies
   - Unmet need in type 2 diabetes
8. **Drug Pipeline** *(powered by Cortellis)*
9. **Appendix**

Report format

- **In-depth written analyses** available on Clarivate's Insights Platform or as a PDF download
- Succinct **Executive Summary** deck
- **Market Forecast Assumptions** (flat data file providing comprehensive view of the 10-year, annualized, patient-based market forecast assumptions, including a detailed methodology)
- **Market Forecast Dashboard** (interactive tool to help understand, interpret, explore, and visualize key outputs from the market forecast)

Clarivate™

Sample content

Question answered

What are the expected sales of key drugs used to treat type 2 diabetes in the G7 markets over the next 10 years?

Disease Landscape & Forecast

Sample content

Question answered

What are the key events impacting the type 2 diabetes market over the forecast period?

Sample content

Question answered

What is the current treatment paradigm for type 2 diabetes?

Sample content

Question answered

What are the opinions of clinical thought leaders regarding the therapies in development for type 2 diabetes?

Overall perception

"Pills are always easier than injections. Moreover, orforglipron is better as it is not a peptide. Such molecules get absorbed much more easily. The problem is the level of weight loss we have been able to reach with tirzepatide, it is going to be very difficult to do it with oral medications." —Endocrinologist, United States

"It will be a competitor for Rybelsus with the advantage of not needing the dosing limitations. However, we have and will have CV data for Ozempic, Mounjaro, and Rybelsus. It will be tricky for orforglipron to penetrate the market. Orforglipron will need to have CV safety and maybe clinical superiority to established drugs." —Endocrinologist, United Kingdom

Daily vs. weekly formulation

"I do not see any reason to think that weekly formulations will be substantially different from daily basal insulin. We have all these different products, and some are slightly better than others in one way or another, but they are all very similar overall. The same is going to be true with the once weekly insulins." —Endocrinologist, United States

Clarivate™

Sample content

Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?

Last updated: October 2024

About Clarivate
Disease Intelligence and Analytics

Disease intelligence you can trust

Size your market

Understand global and local markets, by gauging the size of the drug treatable population, where they're located, and how populations will change over time.

Identify unmet needs

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity.

Fuel successful market access

Optimize your market access strategy with brand-level insight regarding the impact of payer policy on physician prescribing behavior.

Assess and prioritize opportunities

Evaluate market potential for your assets – and those of your competitors – and optimize your strategy with indication-specific market intelligence combined with world-class epidemiology.

Understand the patient journey

Gain visibility into brand usage by line of therapy with RWD and uncover the 'why' behind treatment pathways and brand usage with in-depth coverage of physician perceptions on disease management.

Optimize your brand positioning

Analyze treatment pathways across highly dynamic oncology indications to support brand positioning, strategic planning, and business development.

Find out more

Learn more about how Clarivate can help you maximize your market share:
clarivate.com/products/
biopharma/portfolio-strategy-
business-development

Think forward™

Contact our experts today:
healthcare.support@clarivate.com
clarivate.com